|
1）Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390: 45-51
|
|
|
|
2）Kuro-o M. Klotho in health and disease. Curr Opin Nephrol Hypertens. 2012; 21: 362-8
|
|
|
|
|
|
3）Shimada T, Kakitani M, Yamazaki Y, et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113: 561-8
|
|
|
|
|
|
4）Hu MC, Kuro-o M, Moe OW. The emerging role of Klotho in clinical nephrology. Nephrol Dial Transplant. 2012; 27: 2650-7
|
|
|
|
|
|
5）John GB, Cheng CY, Kuro-o M. Role of Klotho in aging, phosphate metabolism, and CKD. Am J Kidney Dis. 2011; 58: 127-34
|
|
|
|
|
|
6）Hu MC, Shiizaki K, Kuro-o M, et al. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013; 75: 503-33
|
|
|
|
|
|
7）Chen CD, Podvin S, Gillespie E, et al. Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc Natl Acad Sci U S A. 2007; 104: 19796-801
|
|
|
|
|
|
8）Lim K, Lu TS, Molostvov G, et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012; 125: 2243-55
|
|
|
|
|
|
9）Donate-Correa J, Muros de Fuentes M, Mora-Fernandez C, et al. Pathophysiological implications of fibroblast growth factor-23 and Klotho and their potential role as clinical biomarkers. Clin Chem. 2013 Jun 11 [Epub ahead of print]
|
|
|
|
|
|
10）Heijboer AC, Blankenstein MA, Hoenderop J, et al. Laboratory aspects of circulating alpha-Klotho. Nephrol Dial Transplant. 2013; 28: 2283-7
|
|
|
|
|
|
11）Yamazaki Y, Imura A, Urakawa I, et al. Establishment of sandwich ELISA for soluble alpha-Klotho measurement: Age-dependent change of soluble alpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun. 2010; 398: 513-8
|
|
|
|
|
|
12）Ohata Y, Arahori H, Namba N, et al. Circulating levels of soluble alpha-Klotho are markedly elevated in human umbilical cord blood. J Clin Endocrinol Metab. 2011; 96: E943-7
|
|
|
|
|
|
13）Carpenter TO, Insogna KL, Zhang JH, et al. Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status. J Clin Endocrinol Metab. 2010; 95: E352-7
|
|
|
|
|
|
14）Semba RD, Cappola AR, Sun K, et al. Plasma klotho and cardiovascular disease in adults. J Am Geriatr Soc. 2011; 59: 1596-601
|
|
|
|
|
|
15）Semba RD, Cappola AR, Sun K, et al. Plasma klotho and mortality risk in older community-dwelling adults. J Gerontol A Biol Sci Med Sci. 2011; 66: 794-800
|
|
|
|
|
|
16）Semba RD, Cappola AR, Sun K, et al. Relationship of low plasma klotho with poor grip strength in older community-dwelling adults: the InCHIANTI study. Eur J Appl Physiol. 2012; 112: 1215-20
|
|
|
|
|
|
17）Kitagawa M. A decreased level of serum soluble klotho is an independent biomarker associated with arterial stiffness in patients with chronic kidney disease. PLoS One. 2013; 8: e56695
|
|
|
|
|
|
18）Pavik I, Jaeger P, Ebner L, et al. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant. 2013; 28: 352-9
|
|
|
|
|
|
19）Shimamura Y, Hamada K, Inoue K, et al. Serum levels of soluble secreted alpha-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol. 2012; 16: 722-9
|
|
|
|
|
20）Wan M, Smith C, Shah V, et al. Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease. Nephrol Dial Transplant. 2013; 28: 153-61
|
|
|
|
|
|
21）Koh N, Fujimori T, Nishiguchi S, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun. 2001; 280: 1015-20
|
|
|
|
|
|
22）Yokoyama K, Imura A, Ohkido I, et al. Serum soluble alpha-klotho in hemodialysis patients. Clin Nephrol. 2012; 77: 347-51
|
|
|
|
|
|
23）Seiler S, Wen M, Roth HJ, et al. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int. 2013; 83: 121-8
|
|
|
|
|
|
24）Devaraj S, Syed B, Chien A, et al. Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol. 2012; 137: 479-85
|
|
|
|
|
|
25）Kacso IM, Bondor CI, Kacso G. Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A. Clin Biochem. 2012; 45: 1415-20
|
|
|
|
|
|
26）Pavik I, Jaeger P, Ebner L, et al. Soluble klotho and autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012; 7: 248-57
|
|
|
|
|
|
27）Kim HR, Nam BY, Kim DW, et al. Circulating alpha-klotho levels in CKD and relationship to progression. Am J Kidney Dis. 2013; 61: 899-909
|
|
|
|
|
|
28）Akimoto T, Kimura T, Watanabe Y, et al. The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein. Transplant Proc. 2013; 45: 134-6
|
|
|
|
|
|
29）Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010; 77: 292-8
|
|
|
|
|
|
30）Komaba H, Goto S, Fujii H, et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int. 2010; 77: 232-8
|
|
|
|
|
|
31）Donate-Correa J, Mora-Fernandez C, Martinez-Sanz R, et al. Expression of FGF23/KLOTHO system in human vascular tissue. Int J Cardiol. 2013; 165: 179-83
|
|
|
|
|
|
32）Lim SC, Liu JJ, Subramaniam T. Elevated circulating alpha-klotho by angiotensin II receptor blocker losartan is associated with reduction of albuminuria in type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst. 2013 Feb 4 [Epub ahead of print]
|
|
|
|
|
|
33）Komaba H, Koizumi M, Tanaka H, et al. Effects of cinacalcet treatment on serum soluble Klotho levels in haemodialysis patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2012; 27: 1967-9
|
|
|
|
|
|
34）Hu MC, Shi M, Zhang J, et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 124-36
|
|
|
|
|
|
35）Hu MC, Shi M, Zhang J, et al. Klotho deficiency is an early biomarker of renal ischemia-reperfusion injury and its replacement is protective. Kidney Int. 2010; 78: 1240-51
|
|
|
|
|
|
36）Akimoto T, Yoshizawa H, Watanabe Y, et al. Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol. 2012; 13: 155
|
|
|
|
|
|
37）Akimoto T, Shiizaki K, Sugase T, et al. The relationship between the soluble Klotho protein and the residual renal function among peritoneal dialysis patients. Clin Exp Nephrol. 2012; 16: 442-7
|
|
|
|
|
|
38）Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012; 82: 737-47
|
|
|
|
|